Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours By Ogkologos - February 17, 2026 327 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DELII study Source RELATED ARTICLESMORE FROM AUTHOR Multicancer early detection test detects tumour-derived cfDNA and demonstrates robust performance characteristics with a favourable safety profile Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Relacorilant MOST POPULAR A Cancer Revolution comes to Manchester: Patrick’s review November 24, 2021 Sleep Issue Called Hypersomnolence Can Increase The Risk Of Diabetes And... May 14, 2020 Mom Finding Out Baby’s Gender Uncovers Rare Condition When Doctors See... November 7, 2019 Addressing Disparities and Raising Awareness During National Black Family Cancer Awareness... June 15, 2023 Load more HOT NEWS Survival According Circulating Tumour DNA Status in the Study of Adjuvant... Stringently Defined Clinical Complete Response After Gemcitabine, Cisplatin, Plus Nivolumab Facilitates... ELCC 2015 News: ‘Real-World’ EGFR Mutation Frequency Results From a Large... 37-Year-Old Mom Breaks American Marathon Record
